2Aguayo A , Kantarjian HM,Estey EH, et al. Plasma vascular endothelial growth factor levels have prognostic signicance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes . cancer , 2002, 95 (9):1923-1930.
3Verstovsek S,Estey E,Nanshouri T,et al. Clinical relevance of vascular endothelial growth factor receoptors 1 and 2 in acute myeloid leukemia and myelodysplastic syndromes . Br J Haematol,2002,118(1):151-156.
4Peuckmann V, Fisch M, Bruera E, et al. Potantial novel uses of thalidomide: focus on palliative care . Drugs, 2000,60（2）:273-292.
5Zorat F, Shetty v, Dutt D, et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes .Br J Haematol,2001,115(4) : 881-894.
6Strupp C, Germing U, Aivado M, et al. Thalidomide for the treatment of patients with myelodysplastic syndromes . leukemia,2002,16(1):1-6.
7Raza A, Meyer P, Dutt D , et al. thalidomide produces transfusion independence in log-standing refractory anemias of patients with myelodysplastic syndromes .Blood ,2001,98(4):958-965.
8Zangan M, Anaissie E, Desikan R, et al. Thalidomide induced hypercoagulability in multiple myeloma. Blood, 2000,96(11):269b.
